Evidence-informed monographs, oncology & high-alert drug protocols, pharmacognosy botanical profiles, cosmetic science (INCI), ICMR/FSSAI nutraceuticals, clinical calculators, and Indian regulatory law for students, pharmacists, and educators.
Complete compendial drug monographs across cardiovascular, endocrine, antimicrobial, CNS, respiratory, renal, and GI therapeutics with verified Indian brands.
Alkylating agents, antimetabolites, anthracyclines, platinum complexes, taxanes, hormonal therapies, targeted TKIs (-nib), mAbs (-mab), checkpoint inhibitors, and supportive care.
Schedule H1, Schedule X, NDPS Essential Narcotic Drugs (ENDs), WHO AWaRe Reserve antibiotics, NTEP DR-TB agents, REMS teratogens, and ICU anaesthetics.
Pharmacognosy profiles with accepted Latin binomials, authenticated plant parts, HPTLC/HPLC phytochemical markers, clinical evidence vs traditional use, and herb–drug interactions.
Dermopharmaceutics profiles with INCI nomenclature, evidence-backed concentration & pH windows, chemical incompatibilities, and Cosmetics Rules, 2020 vs Drug boundaries.
Vitamins, chelated minerals, omega-3s, probiotics, carotenoids, and amino derivatives with ICMR-NIN 2024 RDA/UL limits, bioavailability, and FSSAI Nutraceutical regulations.
40 structured, referenced guides covering clinical pharmacotherapy, oncology supportive care, Schedule H/H1/X law, herb–drug interactions, label reading, and ADME pharmacokinetics.
32 interactive clinical & pharmaceutical calculators, D.Pharm/B.Pharm/Pharm.D/GPAT study resources, and Indian Pharmacy Jurisprudence (Drugs & Cosmetics Act, NDPS, DPCO).
Dihydropyridine CCB antihypertensive; 2.5 mg, 5 mg, 10 mg tablets (Stamlo, Amlogard, Amlopres).
WHO Reserve / Schedule H1 DBO beta-lactamase inhibitor combination for KPC/OXA-48 CRE infections.
Mycobacterial ATP synthase inhibitor for MDR/XDR-TB (BPaLM regimen); QTc & food-effect protocol.
3rd-gen mutant-selective EGFR TKI (Ex19del, L858R, T790M) in NSCLC with CNS penetration.
Humanised anti-PD-1 immune checkpoint inhibitor; irAE corticosteroid management protocol.
Solanaceae dried mature root; withanolide HPTLC markers, RCT cortisol data, and DILI/thyroid precautions.
2%–5% barrier ceramide booster & melanosome transfer inhibitor (pH 5.5–7.0; Cosmetics Rules 2020).
Acid-independent water-soluble calcium salt; ICMR-NIN 2024 RDA (1,000–1,200 mg) & iron/thyroxine spacing.
Statutory comparison of prescription rules, 3-year H1 register vs 2-year Schedule X retention, and END narcotics.
Cell-cycle specificity, Calvert & BSA dosing, oral TKI food traps, and PD-1/PD-L1 checkpoint blockade.
Isabgol mucilage trapping, Shankhpushpi–phenytoin drop, Mulethi pseudoaldosteronism, and green tea–bortezomib antagonism.
How CDSCO Drugs & Cosmetics Rules, 2020 and FSSAI Nutraceutical Regulations draw legal boundaries by concentration and claim.
Why loading doses stay unchanged in CKD while maintenance doses scale with Cockcroft-Gault CrCl and Child-Pugh scores.
Visualising first-pass extraction, albumin binding, CYP450 Phase I/II biotransformation, and renal pH trapping.
16 Featured High-Resolution Mechanism Plates (ADME 12-Step Journey, Nephron Excretion, CYP450 Hepatocyte Pathways, Receptor Dose–Response Curves, Antimicrobial Targets, RAAS Cascade, Oncology Cell-Cycle/TKI/Checkpoint Mechanisms, Botanical Phytochemistry, Skin Barrier & Sunscreens, and Micronutrient Absorption) + 46 Clinical Reference Plates.
Disintegration, dissolution, enterocyte P-gp/CYP3A4, portal vein first-pass, and renal/biliary clearance.
View Plate 8.1 →Cell-cycle phase specificity (G1, S, G2, M), small-molecule TKIs (-nib), mAbs (-mab), and PD-1/PD-L1 checkpoint release.
View Plate 8.13 →Alkaloids, glycosides, terpenoids, polyphenols, HPTLC marker standardisation, and ASU vs Rule 122E pathways.
View Plate 8.14 →Stratum corneum ceramides (3:1:1), AHA/BHA/Retinol/Niacinamide penetration depths, and UVA1/UVA2/UVB attenuation.
View Plate 8.15 →Access 32 step-by-step clinical and pharmaceutical calculators with formula derivations and sanity bounds, compare any two drug monographs side-by-side across 20 clinical parameters, and study D.Pharm, B.Pharm, Pharm.D, and GPAT reference modules.
THE INDIAN PHARMACIST — Learn. Explore. Practise. Excel. (theindianpharmacist.com) is an independent open-access Indian pharmacy education, clinical drug reference, and pharmaceutical sciences platform conceived, founded, and authored by Tejas Chandrakant Nartam (Tejas Nartam — Founder & Creator, THE INDIAN PHARMACIST).
For academic feedback, compendial errata, or collaboration inquiries, contact: tejas.nartam@gmail.com.
👤 Read Complete Founder Profile & Governance →All 644 Reference Profiles (519 Canonical Medicine Monographs, 30 Restricted/High-Risk Medicines, 30 Oncology Medicines, 25 Medicinal Plants, 20 Cosmetic Ingredients, and 20 Dietary Supplements), 40 Knowledge Hub Articles, and 32 Clinical Calculators are provided strictly for pharmacy education, academic learning, and professional reference.
Content does not substitute for qualified physician diagnosis, specialist oncology treatment protocols, or official CDSCO / Indian Pharmacopoeia (IP) / FSSAI prescribing and labelling regulations. Never self-medicate with prescription medicines.
